abbv-323
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 26, 2019 (NCT03695185)
Timeline
Indications
Mechanism of action
- CD40 ligandANTAGONIST
CD40 ligand antagonist
CD40 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298212 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06972446 | Phase 2 | Jun 20, 2025 | AbbVie |
| NCT06402513 | Phase 1 | Jun 24, 2024 | AbbVie |
| NCT05217472 | Phase 2 | Mar 6, 2020 | AbbVie |
| NCT03695185 | Phase 2 | Mar 26, 2019 | AbbVie |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 4 | 2 | 2019 |
1 organizations
Page 1 / 1